cas 2764851-03-6|| where to buy [(2S)-1,1,1-trifluoropropan-2-yl]hydrazine hydrochloride

Nom du produit:[(2S)-1,1,1-trifluoropropan-2-yl]hydrazine hydrochloride

IUPAC Name:[(2S)-1,1,1-trifluoropropan-2-yl]hydrazine hydrochloride

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM1046608-25g	2-3 Weeks	ƞŔșș

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2764851-03-6 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:2764851-03-6; Formule moléculaire:C3H8ClF3N2; Point de fusion:-; Code SMILES:C[C@@H](C(F)(F)F)NN.Cl; Densité:

: Numéro de catalogue:CM1046608; Poids moléculaire:164.56; Point d'ébullition:; N° Mdl:; Stockage:

: Fluorinated Compounds; Fluorine is the most electronegative element in the periodic table, and the fluorine atom has a small atomic radius, so fluorine-containing organic compounds have many wonderful properties. For example, the introduction of fluorine atoms or fluorine-containing groups into drug molecules can improve the permeability to cell membranes, metabolic stability and bioavailability; in addition, the introduction of fluorine atoms will improve the lipid solubility of the compound and promote its absorption in the body. The speed of delivery changes the physiological effect. In the field of medicinal chemistry, the introduction of fluorine atoms into organic molecules is an important direction for the development of new anticancer drugs, antitumor drugs, antiviral agents, anti-inflammatory drugs, and central nervous system drugs.

: Pirtobrutinib; Eli Lilly and Company announced that the U.S. FDA approved Jaypirca® (Pirtobrutinib) for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor and a BCL-2 inhibitor. Jaypirca (Pirtobrutinib) is a highly selective (300 times more selective for BTK versus 98% of other kinases tested in preclinical studies), non-covalent (reversible) inhibitor of the enzyme BTK.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.